epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-301, Phase III. Recruiting

Non-small cell lung cancer, second line

NWT-4471 with docetaxel against docetaxel alone in previously treated non-small cell lung cancer. Sponsor: Northwind Therapeutics (fictional), Oncology.

Key risk indicators watch each site, as its data arrives, for the risks on this study's Risks tab under Design and risks. A problem shows at the site before it reaches the study's KPIs or QTLs.

Thresholds by country

A country's threshold is tighter than the default only where a sourced country risk supports it: five here. Everywhere else the default applies, because no difference between countries was found.

KRIDefaultUnited StatesUnited KingdomSpainPolandTurkeyIndiaSites over
Site activation overdueDays a site's activation runs past the end of its country's planned start-up window Above 30 days0 daysDefaultDefaultDefault0 days14 days0 of 159
Screen failure above the study'sPercentage points by which a site's screen failure exceeds the study's own, once it has screened enough patients Above +15 pointsDefaultDefaultDefaultDefaultDefaultDefault1 of 3
Data entry lagMedian days from a patient's visit to its data being entered, over the last three months Above 7 daysDefaultDefaultDefaultDefaultDefaultDefault10 of 89
Queries open over 30 daysShare of a site's open data queries that have been open for more than 30 days, over the last three months Above 20%DefaultDefaultDefaultDefaultDefaultDefault7 of 89
Important protocol deviationsImportant protocol deviations per hundred patient-months in the study at the site, so long and short studies compare fairly Above 2DefaultDefaultDefaultDefaultDefaultDefault5 of 18
Consent findingsConsent findings (missing, outdated or incomplete consent records) per hundred patients consented at the site Above 5DefaultDefaultDefaultDefaultDefault0Too early
Study drug at the siteWeeks of study drug held at the site, resupplied early below the threshold Below 4 weeksDefaultDefaultDefaultDefault8 weeksDefaultNot in the data
Enrolment against the diversity planShare of the enrolment goal for each under-represented group met so far, against the study's diversity action plan Below 80%Default–––––Not in the data
  • United States, site activation overdue: 0 days. US sites are activated slowly after the first: 309 days to activate 75% of US sites against 34 to 126 days elsewhere. A late US site is escalated at once. (register PM-03)
  • Turkey, site activation overdue: 0 days. Turkey's ethics committees fell from 145 to 49 in 2024, and nobody has measured the delay that followed. A late Turkish site is escalated at once. (register RW-05)
  • Turkey, study drug at the site: 8 weeks. Turkey has had repeated medicine shortages under its fixed pharmaceutical exchange rate (645 products short in November 2021), so sites hold a larger buffer. (register RW-07)
  • India, site activation overdue: 14 days. Start-up time in India is unmeasured beyond the statutory 90 working days, so a late site is escalated after two weeks rather than a month. (register PM-04)
  • India, consent findings: 0. India requires an audio-visual record of consent from vulnerable participants in trials of new drugs. Any missing record is a finding to act on, not a rate to watch. (register RW-03)

Sites over a threshold

19 out of 159 sites are over at least one threshold, most first. Each is a prompt for the CRA to look, not a finding; the Sites tab shows whether the same sites are behind on recruitment.

SiteOver
301-UK-15, LondonUnited KingdomData entry lag: 8.7 days against 7 daysQueries open over 30 days: 37.3% against 20%Important protocol deviations: 5.6 against 2
301-PL-17, OlsztynPolandData entry lag: 11.6 days against 7 daysQueries open over 30 days: 29% against 20%
301-TR-07, İzmirTurkeyScreen failure above the study's: +28 points against +15 pointsData entry lag: 8.8 days against 7 days
301-ES-02, MadridSpainImportant protocol deviations: 4.1 against 2
301-ES-11, Santiago de CompostelaSpainQueries open over 30 days: 28.3% against 20%
301-ES-12, MálagaSpainData entry lag: 9 days against 7 days
301-ES-16, ZaragozaSpainData entry lag: 7.2 days against 7 days
301-ES-30, AlicanteSpainQueries open over 30 days: 33.7% against 20%
301-ES-31, ZaragozaSpainData entry lag: 7.6 days against 7 days
301-ES-33, SalamancaSpainData entry lag: 14.2 days against 7 days
301-IN-12, LucknowIndiaQueries open over 30 days: 32% against 20%
301-TR-09, AntalyaTurkeyData entry lag: 7.1 days against 7 days
301-UK-02, NewcastleUnited KingdomQueries open over 30 days: 20.3% against 20%
301-UK-14, ManchesterUnited KingdomImportant protocol deviations: 5.9 against 2
301-UK-16, CardiffUnited KingdomImportant protocol deviations: 3.7 against 2
301-UK-24, LiverpoolUnited KingdomQueries open over 30 days: 21.3% against 20%
301-UK-25, NottinghamUnited KingdomData entry lag: 7.1 days against 7 days
301-US-21, HoustonUnited StatesImportant protocol deviations: 5.3 against 2
301-US-29, AtlantaUnited StatesData entry lag: 7.7 days against 7 days

Sources: epiClinical synthetic KRI data, in which levels follow each site's own facts (such as coordinator time), never its country. Readings marked too few wait until a site has enough patients; drug supply and diversity come from systems the synthetic data does not include.